ThunderBio Innovation Limited is a leading biotech company established in 2018. Founded by a team of returnee doctors, entrepreneurs, and management professionals, along with technical teams from The Hong Kong University of Science and Technology and Imperial College London, the company specializes in the development and sale of innovative instruments and reagents for digital liquid biopsy technology based on microfluidic chips (lab on chip) for tumor screening and POCT rapid diagnostics. ThunderBio holds multiple technology patents in the field of tumor diagnostics and microfluidics, boasting a global market presence.

Their product lineup includes the Galaxy single-cell sequencing system, the Comet high-throughput screening system, the Nebula digital PCR system, and more. ThunderBio's solutions have revolutionized the discovery of disease-related findings, providing new perspectives and quick insights into biological research, making them a trusted partner for researchers and medical professionals alike